1

2

3

4
Borchardt Allen John, Kania Robert Steven, Palmer Cynthia Louise: 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases. Pfizer, Borchardt Allen John, Kania Robert Steven, Palmer Cynthia Louise, LUMB J Trevor, July 8, 2004: WO/2004/056806 (4 worldwide citation)

Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted ...


5
Kania Robert Steven, Bender Steven Lee, Borchardt Allen J, Braganza John F, Cripps Stephan James, Hua Ye, Johnson Michael David, Johnson Theodore Otto Jr, Luu Hiep The, Palmer Cynthia Louise, Reich Siegfried Heinz, Tempczyk Russell Anna Maria, Teng Min, Thomas Christine, Varney Michael David, Wallace Michael Brennan, Collins Michael Raymond: Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use. Agouron Pharmaceuticals, PINO Mark J, January 11, 2001: WO/2001/002369 (3 worldwide citation)

Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The inv ...


6
Bender Steven Lee, Bhumralkar Dilip, Collins Michael Raymond, Cripps Stephan James, Deal Judith Gail, Nambu Mitchell David, Palmer Cynthia Louise, Peng Zhengwei, Varney Michael David, Jia Lei: Amide compounds for inhibiting protein kinases. Agouron Pharmaceuticals, GADIANO Christina, July 26, 2001: WO/2001/053274 (2 worldwide citation)

Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invent ...


7
BAILEY Simon, BURKE Benjamin Joseph, COLLINS Michael Raymond, CUI Jingrong Jean, DEAL Judith Gail, HOFFMAN Robert Louis, HUANG Qinhua, JOHNSON Ted William, KANIA Robert Steven, KATH John Charles, LE Phuong Thi Quy, MCTIGUE Michele Ann, PALMER Cynthia Louise, RICHARDSON Paul Francis, SACH Neal William: [fr] DÉRIVÉS MACROCYCLIQUES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES, [en] MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES. Pfizer, KLEIMAN Gabriel L, September 12, 2013: WO/2013/132376 (2 worldwide citation)

[en] The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymp ...


8
Collins Michael Raymond, Tempczyk Russell Anna Maria, Hua Ye, Johnson Michael David, Bender Steven Lee, Kania Robert Steven, Borchardt Allen J, Braganza John F, Cripps Stephan James, Johnson Theodore Otto Jr, Luu Hiep The, Palmer Cynthia Louise, Reich Siegfried Heinz, Teng Min, Thomas Christine, Varney Michael David, Wallace Michael Brennan: Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use. Agouron Pharma, January 11, 2006: EP1614683-A1 (1 worldwide citation)

Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The inv ...


9
Bleckman Ted Michael, Palmer Cynthia Louise, Romines William Henry Iii, Varney Michael David: Compounds useful as aicarft inhibitors. Agouron Pharma, June 27, 2001: EP1109560-A1

Coumpounds of the formula (I) (where R, R, and R are as defined in the specification) are inhibitors of AICARFT. These compounds, as well as their pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutically active metabolites, are useful in pharmaceutical compositions for treating di ...


10